What is Pharmazz?
Headquartered in Willowbrook, Illinois, and established in 2010, Pharmazz, Inc. operates as a specialized biopharmaceutical entity dedicated to the discovery and development of novel therapeutic agents. The company maintains a global footprint, with a strategic operational presence in India through its subsidiary, Pharmazz India Pvt Ltd. Its core focus remains on high-acuity medical conditions, specifically targeting critical care and neurological disorders where current treatment options are often limited or ineffective. By integrating advanced scientific research with a global supply chain, Pharmazz aims to bridge the gap between laboratory innovation and patient-centric clinical outcomes.
How much funding has Pharmazz raised?
Pharmazz has raised a total of $40M across 2 funding rounds:
Private Equity
$15M
Private Equity
$25M
Private Equity (2024): $15M with participation from Sun Pharma
Private Equity (2025): $25M led by Sun Pharma
Key Investors in Pharmazz
Sun Pharma
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is headquartered in Mumbai, India.
What's next for Pharmazz?
With this major enterprise-level funding, Pharmazz is poised to transition into a more aggressive phase of clinical development and market expansion. The strategic allocation of these funds will likely prioritize the advancement of its pipeline candidates through late-stage clinical trials, while simultaneously strengthening its commercial infrastructure. As the company continues to scale, the focus will shift toward regulatory milestones and the potential commercialization of its proprietary therapies. This capital backing provides the necessary runway to sustain long-term research efforts and potentially disrupt the standard of care in its targeted therapeutic areas, ensuring that Pharmazz remains at the forefront of biopharmaceutical innovation.
See full Pharmazz company page
